Lancet: Dolutegravir Works as Well as Raltegravir for First-time HIV Treatment

The next-generation HIV integrase inhibitor dolutegravir worked as well as raltegravir (Isentress), an approved drug in this class, for treatment-naive people in the Phase 3 SPRING-2 trial, according to a report published in the January 8, 2013, advance edition of The Lancet.

Read more:

Coverage of 11th International Congress on Drug Therapy in HIV Infection

HIVandHepatitis.com coverage of the 11th International Congress on Drug Therapy in HIV Infection (HIV11), November 11-15, 2012, Glasgow, Scotland.

Conference highlights include experimental antiretroviral drugs, ART strategies, manging side effects, HIV-related non-AIDS conditions, treatment as prevention and PrEP, HIV/HCV coinfection, and the search for a cure for HIV.

Full listing by topic

HIVandHepatitis.com HIV11 conference section

11/17/12

ViiV Submits Integrase Inhibitor Dolutegravir for Approval in the U.S., Europe, and Canada

ViiV Healthcare this week announced that it has requested regulatory approval of its investigational integrase inhibitor dolutegravir in several countries. Dolutegravir (formerly known as S/GSK1349572) has demonstrated potent antiviral activity and a good safety profile in both treatment-experienced and previously untreated HIV patients in Phase 3 clinical trials.

Read more:

HIV11: Dolutegravir Remains Effective for Treatment-experienced People with Multidrug-resistant HIV

The investigational HIV integrase inhibitor dolutegravir, which has shown comparable or superior efficacy to widely used drugs in clinical trials to date, works well for people with highly resistant HIV, including virus with mutations conferring resistance to other drugs in its class, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.

Read more: